How do we correct symptomatic hyponatremia in a patient with severe symptoms, such as seizures or coma, and serum sodium levels below 125 mmol/L?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Symptomatic Hyponatremia

For severe symptomatic hyponatremia (seizures, coma, altered mental status) with sodium <125 mmol/L, immediately administer 3% hypertonic saline with a target correction of 6 mmol/L over 6 hours or until severe symptoms resolve, with total correction not exceeding 8 mmol/L in 24 hours. 1

Immediate Emergency Management

Severe symptoms constitute a medical emergency requiring urgent hypertonic saline, not fluid restriction. 1 Severe symptoms include:

  • Seizures, coma, or altered mental status 1
  • Confusion, delirium, or impaired consciousness 2
  • Respiratory arrest or cardiorespiratory distress 3
  • Somnolence or obtundation 3

Hypertonic Saline Administration Protocol

Administer 3% hypertonic saline as 100-150 mL intravenous boluses over 10 minutes, which can be repeated up to three times at 10-minute intervals until symptoms improve. 1, 4 This rapid intermittent bolus approach is preferred over continuous infusion for symptomatic hyponatremia. 4

The initial infusion rate (mL/kg per hour) can be estimated by: body weight (kg) × desired rate of increase in sodium (mmol/L per hour). 5

Critical Correction Rate Guidelines

The maximum correction must not exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome. 1, 6 This is the single most important safety principle. 1

For the first 6 hours, correct by 6 mmol/L or until severe symptoms resolve. 1 If 6 mmol/L are corrected in the first 6 hours, only 2 mmol/L additional correction is allowed in the remaining 18 hours. 1

High-Risk Populations Requiring Slower Correction

Patients with advanced liver disease, alcoholism, malnutrition, or prior encephalopathy require even more cautious correction at 4-6 mmol/L per day, maximum 8 mmol/L in 24 hours. 1, 7 The FDA label for tolvaptan specifically warns that "in susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable." 6

Overly rapid correction (>12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. 6

Intensive Monitoring Protocol

Check serum sodium every 2 hours during the initial correction phase for patients with severe symptoms. 1 After severe symptoms resolve, monitor every 4 hours. 1

ICU admission is recommended for close monitoring during treatment of severe symptomatic hyponatremia. 1

Management Based on Volume Status

Once symptoms are controlled, determine volume status to guide ongoing management:

Hypovolemic Hyponatremia

  • Discontinue diuretics immediately and administer isotonic saline (0.9% NaCl) for volume repletion. 1, 2
  • Urine sodium <30 mmol/L predicts good response to saline infusion. 1

Euvolemic Hyponatremia (SIADH)

  • After symptom resolution, implement fluid restriction to 1 L/day. 1
  • If no response to fluid restriction, add oral sodium chloride 100 mEq three times daily. 1

Hypervolemic Hyponatremia (Heart Failure, Cirrhosis)

  • Implement fluid restriction to 1-1.5 L/day for sodium <125 mmol/L. 1
  • Avoid hypertonic saline unless life-threatening symptoms are present, as it may worsen fluid overload. 1
  • Consider albumin infusion in cirrhotic patients. 1

Special Considerations for Neurosurgical Patients

In neurosurgical patients, distinguish between SIADH and cerebral salt wasting (CSW), as they require opposite treatments. 1

CSW is characterized by:

  • True hypovolemia with low central venous pressure (<6 cm H₂O) 1
  • High urine sodium >20 mmol/L despite volume depletion 1
  • Clinical signs of volume depletion (hypotension, tachycardia, dry mucous membranes) 1

CSW requires volume and sodium replacement with isotonic or hypertonic saline, NOT fluid restriction. 1 For severe symptoms, add fludrocortisone 0.1-0.2 mg daily. 1

Never use fluid restriction in subarachnoid hemorrhage patients at risk of vasospasm. 1

Management of Overcorrection

If sodium correction exceeds 8 mmol/L in 24 hours, immediately discontinue current fluids and switch to D5W (5% dextrose in water). 1 Consider administering desmopressin to slow or reverse the rapid rise in serum sodium. 1, 7

Recent experimental data suggest that rapidly decreasing serum sodium through hypotonic fluids and dDAVP in overly corrected patients could greatly reduce the risk of myelinolysis. 7

Common Pitfalls to Avoid

  • Never use fluid restriction as initial treatment for altered mental status from hyponatremia—this is a medical emergency requiring hypertonic saline. 1
  • Never exceed 8 mmol/L correction in 24 hours—overcorrection risks osmotic demyelination syndrome. 1
  • Inadequate monitoring during active correction is a common pitfall. 1
  • Using fluid restriction in cerebral salt wasting worsens outcomes. 1
  • Failing to recognize and treat the underlying cause can lead to poor outcomes. 1

Role of Vaptans

Tolvaptan should be initiated and re-initiated only in a hospital where serum sodium can be monitored closely. 6 The FDA label states that "patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets." 6

Vaptans are not appropriate for emergency management of severe symptomatic hyponatremia. 6 They are reserved for euvolemic or hypervolemic hyponatremia that is refractory to fluid restriction. 1

References

Guideline

Management of Sodium Imbalance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hyponatraemia-treatment standard 2024.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.